融泰药业报考港股上市：IPO前夕，深创投减持套现约9000万元

Core Viewpoint - Guangdong Rontai Pharmaceutical Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor. The company focuses on digital marketing and supply chain solutions in the outpatient pharmaceutical service sector [1][3]. Company Overview - Rontai Pharmaceutical was established in May 2004 and is headquartered in Guangzhou, Guangdong Province. The company has a registered capital of approximately 10.53 million yuan [4]. - The major shareholders include Guangzhou Changfeng, Chen Changqing, and Zhao Haifeng, with Chen Changqing being the actual controller and chairman of the board [4][9]. Market Position - According to Frost & Sullivan, Rontai Pharmaceutical is the fourth largest provider of marketing and supply chain solutions in China's outpatient pharmaceutical market, and the largest provider targeting individual customers [3]. Business Model - The company plays a crucial role in the e-commerce sales channels for pharmaceutical companies, matching them with optimal e-commerce resources. It procures pharmaceutical products from upstream manufacturers and sells them to individual customers through various B2C and O2O platforms [9][10]. - Rontai Pharmaceutical also provides comprehensive e-commerce empowerment services, including brand operation, data monitoring, and inventory management solutions [9]. Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately 2.43 billion yuan, 2.92 billion yuan, 2.88 billion yuan, and 1.54 billion yuan, respectively. The net profits for the same periods were approximately 14.78 million yuan, 45.72 million yuan, 3.74 million yuan, and 17.09 million yuan [10][11]. - The primary revenue source comes from digital sales targeting individual customers, contributing approximately 1.58 billion yuan, 1.69 billion yuan, 1.69 billion yuan, and 862 million yuan, accounting for 65.4%, 57.9%, 58.6%, and 56.0% of total revenue, respectively [11].